Novo Nordisk faces FDA scrutiny over unreported Ozempic side effects, including deaths and a suicide, amid struggles to compete with Eli Lilly in the US obesity drug market. Despite risks like nausea and pancreatitis, Ozempic helps control blood sugar, slow digestion, and reduce appetite.
